TRACON Pharmaceuticals, Inc. reported earnings results for the fourth quarter ended December 31, 2022. For the fourth quarter, the company reported net loss was USD 7 million compared to USD 7.71 million a year ago. Basic loss per share from continuing operations was USD 0.31 compared to USD 0.4 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.49 USD | -1.97% | +4.20% | -57.45% |
14/05 | Transcript : TRACON Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 14, 2024 | |
14/05 | Earnings Flash (TCON) TRACON PHARMACEUTICALS Posts Q1 Revenue $100,000 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-57.45% | 33.9L | |
-2.10% | 9TCr | |
-1.18% | 3.92TCr | |
-15.83% | 3.17TCr | |
+62.10% | 2.65TCr | |
-21.68% | 1.43TCr | |
-8.73% | 1.29TCr | |
-15.05% | 1.12TCr | |
-45.69% | 1.1TCr | |
+3.60% | 894.43Cr |
- Stock Market
- Equities
- TCON Stock
- News TRACON Pharmaceuticals, Inc.
- TRACON Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022